Rotigotine improves restless legs syndrome: A 6-month randomized, double-blind, placebo-controlled trial in the United States

Movement Disorders

Volumn 25, Issue 11, 2010, Pages 1675-1683

  Hening, Wayne A ^a   Allen, Richard P ^b   Ondo, William G ^c   Walters, Arthur S ^d   Winkelman, John W ^e   Becker, Philip ^f   Bogan, Richard ^g   Fry, June M ^h   Kudrow, David B ⁱ   Lesh, Kurt W ^j   Fichtner, Andreas ^k   Schollmayer, Erwin ^k  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h Center for Sleep Medicine   (United States)

ⁱ Neurological Research Institute   (United States)

^j Lynn Institute of the Rockies   (United States)

^k Schwarz Pharma AG   (Germany)

more..

Author keywords

Daytime night time symptoms; Dopamine agonist; Quality of life; Restless legs syndrome; Rotigotine transdermal patch

Indexed keywords

PLACEBO; ROTIGOTINE;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; FATIGUE; FEMALE; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; INFLAMMATION; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SINUS BRADYCARDIA; SKIN IRRITATION; SKIN MANIFESTATION; SOMNOLENCE; SYMPTOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77955823451     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23157     Document Type: Article

References (34)

1. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916-922.
2. Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006;13:1049-1065.
3. Hening WA. Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007;120:S22-S27.
4. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.
5. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-276. (Pubitemid 46148338)
6. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-520.
7. Stiasny-Kolster K, Kohnen R, Schollmayer E, Möller JC, Oertel WH;the Rotigotine SP 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-1438.
8. Oertel WH, Beneš H, García-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-239.
9. Oertel WH, Beneš H, García-Borreguero D, et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008;9:865-873.
10. Oertel WH, Beneš H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome - a randomized, placebo-controlled polysomnographic study. Sleep Med (In Press).
11. Trenkwalder C, Beneš H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604.
12. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.
13. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
14. National Institute of Mental Health. 028 CGI. Clinical global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976. p 217-222.
15. Kohnen R, Stiasny-Kolster K, Oertel WH, Beneš H, Trenkwalder C. Severity rating of restless legs syndrome: validation of the RLS-6 scales. Sleep 2004;27(Abstract Suppl):A342.
16. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham, NC: Duke University Press; 1992. p 235-259.
17. Zung WW. The role of rating scales in the identification and management of the depressed patient in the primary care setting. J Clin Psychiatry 1990;51(Suppl 6):72-76.
18. Kohnen R, Beneš H, Heinrich CR, Kurella B. Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire. Mov Disord 2002;17(Suppl 5):P743.
19. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-365.
20. García-Borreguerro D, Högl B, Ferini-Strambi L, et al. Validation of the Augmentation Severity Rating Scale (ASRS): results from a study of the European restless legs syndrome group (EURLSG). Sleep Med 2005;6(Suppl.2):S67-S68.
21. García-Borreguerro D, Kohnen R, Högl B, et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007;8:455-463.
22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
23. García-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006;10:153-167.
24. Stiasny-Kolster K, Beneš H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004;63:2272-2279.
25. Oertel WH, Beneš H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006;67:1040-1046. (Pubitemid 44454600)
26. Trenkwalder C, Beneš H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007;22:696-703.
27. Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007;16:617-624.
28. García-Borreguero D. Long-term safety and efficacy of rotigotine in idiopathic RLS: 3-year results from a multinational, open-label trial. J Sleep Res 2008;17(Suppl 1):113; P68 Abstract.
29. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-1039.
30. Trenkwalder C, García-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-97.
31. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423.
32. García-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine - International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-530.
33. García-Borreguero D, Ferini-Strambi L, Kohnen R. Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials. Eur J Neurol 2008;15(Suppl 3):110;P1293 Abstract.
34. Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006;5:878-886.